Skip to main content
. Author manuscript; available in PMC: 2021 Oct 27.
Published in final edited form as: ACS Nano. 2020 Sep 25;14(10):13343–13366. doi: 10.1021/acsnano.0c05194

Figure 2. MTO generates a strong ICD response in CT26 colon cancer cells.

Figure 2.

(A) CRT surface detection by flow cytometry. CT26.WT cells were treated by MTO, DOX, and OXA at 1 and 10 μM for 24 h. (B) In Vitro measurement of extracellular HMGB1 release by CT26.WT cells after exposure to MTO, DOX, and OXA treatments for 24h. HMGB1 levels were determined in the cellular supernatants by an ELISA kit. Data are presented as fold-change (mean ± S.D., n = 3) when compared to the untreated group (ANOVA, post hoc = Fisher’s, *p < 0.05, ***p < 0.001, ****p < 0.0001).